As of Friday, December 19, Werewolf Therapeutics, Inc.’s HOWL share price has surged by 9.05%, which has investors questioning if this is right time to sell.

Companies working on air defence, sensitive electronics and other defence applications have been targeted. Read more at ...

Citizens downgraded Werewolf Therapeutics (HOWL) to Market Perform from Outperform without a price target after the company provided updates to ...

As previously reported, Wedbush downgraded Werewolf Therapeutics (HOWL) to Neutral from Outperform with a price target of $1, down from $3. The ...

Recent cyber attacks have targeted Russian defense firms using AI-generated documents as bait, a tactic attributed to the pro ...

Recent cyberattacks have targeted Russian defense companies using AI-generated decoy documents. This campaign, attributed to ...

As of Thursday, December 18, Werewolf Therapeutics, Inc.’s HOWL share price has dipped by 41.36%, which has investors questioning if this is right time to buy.

WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of post-ICI advanced or ...

A wide-ranging look at werewolf folklore, global shapeshifter myths, medical explanations, and the cultural history behind it ...

Before making Thriller, Michael Jackson looked to a 1981 horror classic, with An American Werewolf in London influencing the video’s vision.

Robert Eggers’ 'Werwulf' could redefine werewolf horror in 2026 with brutal medieval folklore and a fearless Christmas Day release.​ ...